The morbidity and mortality of prostate cancer have been increasing recently, and the comprehensive treatment for prostate cancer is unable to achieve satisfactory outcomes.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Quercetin is a natural flavonoid compound that has attracted increased interest and attention due to its anticancer activity. In vitro and in vivo studies have verified that quercetin effectively inhibits prostate cancer via various mechanisms. Clinical trails concerning the pharmacokinetics and application of quercetin in humans have also obtained promising results. Meanwhile, epidemiologic studies have demonstrated a negative association between quercetin intake and prostate cancer incidence and have suggested a chemopreventive effect of quercetin on prostate cancer that has been exhibited in animal experiments. The main issue concerning quercetin utilization is its low bioavailability. Therefore, solutions to the issues concerning its use such as alteration of the molecular structure and combination therapy are in the exploratory stage. In the present review, the most important aspects of chemotherapeutic and chemopreventive effects, mechanisms and clinical application potential of quercetin in prostate cancer are summarized.
Yang F, Song L, Wang H, Wang J, Xu Z, Xing N. Are you the author?
Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China; Department of Reproductive Immunology and Pharmacology, National Research Institute for Family Planning, Beijing 100081, P.R. China; Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China; Institute of Neuroscience, Beijing Key Laboratory of Neural Regeneration and Repair, Capital Medical University, Beijing 100069, P.R. China.
Reference: Oncol Rep. 2015 Jun;33(6):2659-68.